Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.
Kisspeptin-10 half-life: 3-4 minutes in circulation. Kisspeptin-54: slightly longer but still very short (under 10 min). Ultra-short duration mandates pulsatile dosing every 90-120 minutes. Continuous exposure causes rapid receptor desensitization.
Understanding Kisspeptin's Ultra-Short Half-Life
Kisspeptin-10: 3-4 minute elimination half-life. Kisspeptin-54: ~5-10 minute half-life (studies vary). This rapid clearance distinguishes kisspeptin from longer-acting peptides requiring daily administration. Short half-life necessitates frequent dosing (90-120 min intervals) to maintain sustained GnRH neuron stimulation.
Why Short Half-Life Requires Pulsatile Dosing
Continuous kisspeptin exposure (if sustained via infusion) causes GnRH neuron desensitization within 24-48 hours. Pulsatile stimulation (bolus doses separated by periods of no exposure) preserves receptor sensitivity indefinitely. This mirrors natural kisspeptin neuron firing patterns—brief bursts followed by quiet periods.
Pulsatile vs Continuous Administration Efficacy
Pulsatile kisspeptin: maintains LH elevation indefinitely, works for 3-6+ cycles without tolerance. Continuous infusion: LH response collapses 24-48 hours into treatment. Clinical data strongly supports pulsatile as only viable long-term approach. All successful human protocols use pulsatile administration.
Dosing Interval Optimization: 90 vs 120 Minutes
90-minute intervals: more injections (8 daily), slightly more robust GnRH stimulation. 120-minute intervals: fewer injections (6 daily), easier compliance. Both effective; choice depends on convenience vs maximal stimulation preference. Most users report equivalent fertility outcomes at either interval.
Reconstitution Stability and Half-Life
In solution (reconstituted peptide): kisspeptin degrades over time, losing potency. Refrigerated (2-8°C): remains stable 30-45 days. Freezing: damages peptide structure, reduces efficacy. Protect from light: UV exposure accelerates degradation. Proper storage directly impacts peptide half-life and clinical efficacy.
Temperature Effects on Peptide Degradation
Room temperature: rapid degradation (hours). Refrigerated (4°C): slow, linear degradation (days/weeks). Frozen (-20°C): structure damage, reduced efficacy upon thawing. Repeated freeze-thaw: catastrophic structure loss. Maintain consistent 2-8°C refrigeration for optimal half-life preservation throughout 30-45 day window.
Predicting Hormone Response Timing
LH response: ~30 minutes post-injection. Peak LH: ~30-45 minutes. Return to baseline: ~90-120 minutes. This 90-120 minute pharmacokinetic window explains standard pulsatile interval selection. Dosing at 90-120 min maintains continuous stimulation through overlapping LH pulses.
Comparison to Other Peptide Half-Lives
Growth hormone: 10-20 min (requires less frequent dosing). GHRP-6: similar 3-4 min (requires pulsatile). CJC-1295: 30+ min (less frequent dosing). Sermorelin: 7-8 min (pulsatile beneficial). Kisspeptin's short half-life typical for GnRH-acting peptides, dictating frequent administration necessity.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →FAQ
Why can't continuous kisspeptin work?
Continuous exposure causes GnRH neuron receptor desensitization. LH response collapses 24-48 hours into continuous treatment. Pulsatile interruptions reset receptor sensitivity, allowing sustained efficacy. Evolution designed natural GnRH neurons for pulsatile input, not continuous stimulation.
What's the maximum dosing interval?
Beyond 120-150 minutes, GnRH neural firing pattern becomes disrupted. Some users report diminished efficacy at 150+ min intervals. Stick to 90-120 min standard for optimal results.
Does half-life change with weight or age?
Possibly slight variations, but clinical data shows 3-4 min half-life consistent across age/weight ranges. No dose adjustment for half-life needed; weight-based dosing addresses this.
Can I extend peptide shelf-life beyond 45 days?
Not recommended. Kisspeptin degrades linearly; by day 45, significant potency loss occurs. Using older vials reduces efficacy. Prepare fresh vials or plan cycles around 30-45 day stability window.
Does freezing peptide preserve it longer?
No. Freezing damages peptide structure. Thawed peptide shows reduced efficacy. Continuous 2-8°C refrigeration optimal. Freezing is for lyophilized (dry) peptide only; avoid freezing reconstituted solution.
Why is 30-min response time important?
30-min LH peak timing allows timing of subsequent doses to maintain pulsatile elevation. If response takes 60+ min, 90-min intervals become suboptimal. Rapid response validates protocol design.